Aspects of Urological Tissue Engineering by Sharma, Arun K. & Rozkiewicz, Dorota I.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
14 
Aspects of Urological Tissue Engineering 
Arun K. Sharma1,2,3 and Dorota I. Rozkiewicz3,4 
1Children’s Memorial Hospital, Chicago Division of Pediatric Urology 
 2Northwestern University Feinberg School of Medicine, Department of Urology 
3Northwestern University, Institute for BioNanotechnology in Medicine (IBNAM) 
4Northwestern University, Department of Chemistry 
USA  
1. Introduction 
Factors affecting the homeostasis of the urological system stem from a multitude of different 
sources that include developmental miscues to aberrant signaling pathways leading to 
malignant transformations.  In order to create functional tissues that can act as surrogate 
tissues while simultaneously mimicking endogenous anatomical and physiological 
functions, strategies utilizing regenerative medicine based methodologies must be 
employed. The urological system is comprised of the kidneys and their corresponding 
ureters; the bladder and sphincter as well as aspects of the genitourinary system. The 
complex architectural makeup and intricate physiological processes of the urological 
system at the gross and microscopic levels make tissue engineering attempts to 
recapitulate these tissues a very difficult and arduous process. Although great strides 
have been made in the field of urological tissue engineering over the last two decades, the 
clinical needs of patients suffering from urological defects have largely gone unfulfilled. 
However,  the advent of novel approaches that span multiple disciplines including the 
material and clinical sciences as well as the constantly evolving field of stem cell biology 
have curtailed these issues to some extent. This Chapter will delve into strategies that are 
currently utilized for urological based tissue engineering while also providing alternative 
tactics to prevailing approaches.  
2. Conditions affecting the urological system 
2.1 The kidney 
A simplistic overview of nephrogenesis proceeds as three sequential yet overlapping phases 
during human embryogenesis. During the third to fourth week of development, primitive 
cell populations derived from intermediate mesoderm converge upon the cervical region of 
the embryo to form one of two transitory structures termed the pronephros. (McCrory, 1974) 
These converging cell groups form rudimentary excretory units or nephrotomes that join 
with the pronephric duct. Although the pronephros is non-functional in mammals, it serves 
as a precursor structure for the slightly more defined mesonephros. (McCrory, 1974)  The 
progressive development of the definitive kidney continues as the pronephros regresses and 
the development of mesenophric ducts again derived from intermediate mesoderm becomes 
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apparent. (Pelliniemi, 1983) The mesonephros is composed of two distinct structures, the 
mesenophric ducts and the mesonephric tubules. The mesonephric tubules acquire a bed of 
capillaries and are analogous in physiological function as well as anatomic structure to adult 
nephrons in the definitive kidney. These elementary nephrons include the glomerulus, renal 
corpuscles, and Bowman’s capsule.  The mesonephric ducts (Wolffian ducts) eventually give 
rise to the epididymis, the vas deferens, and the seminal vesicles in males and as vestigial 
organs in females. (McCrory, 1974; Hannema, 2006; Welsh, 2006)  An outpocketing from the 
mesonephric duct arises during the fifth to six week of development to form the ureteric 
bud which becomes the decisive ureter as well as the collecting system found within the 
kidney including major and minor calyces, and the renal pelvis within the final stage of 
kidney formation, the metanephros. (McCrory, 1974; Fischer, 2001)  The physiological 
aspects of kidney function are numerous in nature and non-exclusively include hormone 
production and regulation, homeostatic balance, pH and blood pressure control, waste 
removal and nutrient re-absorption. It is therefore imperative that the various physiological 
aspects of the kidney remain under proper control and maintenance. The introduction of 
insult in the forms of either trauma or aberrant developmental events can signify a poor 
outcome for the patient.  
Congenital abnormalities of the kidney and urinary tract (CAKUT) occur in 1 out of 500 
newborns which constitutes approximately 30% of all prenatal anomalies. (Toka, 2010)  
These include a plethora of conditions including horse-shoe kidney, ureter 
malformation/abnormalities, renal hypoplasia, renal agenesis, polycystic kidney disease, 
and Wilms’ tumor formation and can arise at varying stages of the developmental process. 
(Toka, 2010; Stahl, 2006; Gimpel, 2010; Acien, 2010)  Depending upon the severity of the 
malformation and organs affected, various strategies can been utilized to treat patients 
afflicted with CAKUT that include surgical and conservative management. However, even 
with treatment, kidney and urinary tract functions are typically far from ideal. Certain 
signaling pathways have been elucidated but only scratch the surface of this complex 
disorder. (Stahl, 2006; Nakanishi, 2003) 
Aside from congenital defects affecting the kidney, acute and chronic conditions also pre-
dispose patients to poor clinical outcomes. Acute renal failure occurs with rapid onset and 
can result in loss of kidney function with eventual renal failure. (Bellomo, 2004; de 
Mendonca, 2000)  As there are myriad circumstances that may cause acute kidney failure, it 
is a life threatening situation requiring great urgency in order to alleviate the underlying 
cause. Chronic conditions affecting the kidney are also in great number, most notably those 
involved with chronic hypertension and diabetes mellitus. The destruction of the kidney 
due to consistently high blood pressure or continual exposure to copious amounts of 
glucose results in several scenarios in which to manage the disease. Diabetes is the most 
common cause of kidney failure within the United States. Data from the 2011 National 
Diabetes Fact Sheet provided by the American Diabetes Association estimates that there are 
approximately 26 million people living with diabetes within the United States representing 
approximately 8% of the population. (http://www.diabetes.org/diabetes-basic/diabetes-
statistics)   Kidney failure as a result of diabetes accounted for 44% of new cases in 2008 and 
approximately 50,000 people began treatment for end stage kidney disease. Lastly, 
approximately 200,000 people were on either dialysis or underwent kidney transplantation 
as a result of chronic diabetes within the United States.  A total of $348 billion was spent in 
2007 to address diabetes related issues. This stagnating level of evidence suggests a great 
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medical need to overcome current shortcomings involved with kidney disease as tissue 
engineering and nanofabrication strategies for the kidney become more prevalent. 
Kidney transplants and dialysis are the only current means to treat kidney failure. Attempts 
to recapitulate the kidney involve the transplantation of fetal kidneys, the integration of new 
nephrons into the kidney, and the use of embryonic stem cells. Fetal kidney transplantation 
was thought to be a possible means in which to identify tissue for replacement therapies 
since it was believed that fetal tissue did not present the high levels of major 
histocompatibility complexes (MHC) I and II as well as other immunostimulatory antigens.   
Studies performed by Dekel el al demonstrate the use of fetal human kidneys that were 
transplanted beneath the renal capsule of immune deficient rats. (Dekel, 1997a)  Data 
suggests that fetal tissue displayed growth and development for as long as 4 months post-
transplantation without tissue rejection that may have been caused by populations of T- 
cells previously residing in the fetal tissue. Analogous adult tissue underwent graft rejection 
upon stimulus with allogeneic injections of peripheral blood mononuclear cells (PMBC). 
(Dekel, 1997b, 1997c, 2000)  Nephron transplantation became an alternative means in which 
to rejuvenate a faltering kidney. Woolf et al transplanted sections of metanephroi from E13-
E16 mice into the kidney cortex of newborn outbred mice. (Woolf, 1991)  Relevant kidney 
micro-architecture formed over time but complete incorporation of transplanted 
metanephroi was not found in the collecting ducts. A similar study using an analogous 
system (but not identical) failed to produce glomeruli. (Rogers, 1998)   The lack of positive 
data with regard to kidney replacement methodologies leaves alternatives such as 
xenotransplantation with embryonic porcine kidneys. This tissue is not pluripotent but 
rather precursor tissue that has been naturally differentiated along kidney specific 
pathways. (Hammerman, 2011) 
Lastly, highly compelling work by Roy and colleagues appears to be very promising in that 
they have created a bio-artificial implantable device that may take the place of damaged or 
deteriorating kidneys. Preliminary data suggests that this microfluidic bioreactor can mimic 
the physiological conditions found in the kidney with regard to fluid flow rate in the 
presence of kidney epithelial cells. (Ferrell, 2010) Furthermore, Roy et al has determined that 
nanofabricated silicon membranes used in this device demonstrate low levels of 
complement activation, low platelet adhesion, and low blood coagulability. 
(Muthusubramaniam, 2011)  Studies are currently under way to test the feasibility of this 
device in animal models.  
2.2 The ureter 
Conditions which may warrant the replacement of a new ureter include a myriad of 
congenital afflictions including congenital atresia, stricture, bifid ureters as well as ureteral 
cancer and trauma. Arising from the renal pelvis of each kidney, the ureter descends and 
crosses into the urinary bladder. Damage to the valve found at the distal end of each ureter 
can result in vesicoureteral refux with eventually kidney damage if not treated. Within this 
scenario, damage can also manifest itself within the ureters as evidenced by dilated ureters 
caused by increased internal pressures. Tissue transplant studies employed to replace 
defective ureters have been promising. Armatys et al report the use of ileum as a ureteral 
replacement for reconstruction purposes. (Armatys, 2009)   A retrospective study of 91 
patients who underwent ureteral reconstruction using grafted ileum revealed that only 3.3% 
and 6.6% of patients endured long-term anastomotic stricture and fistula, respectively, and 
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had attained normal kidney function.  Other groups have utilized vestigial tissue such as the 
appendix as well as buccal tissue with favorable results. (Dagash, 2008)   Ureters constructed 
from synthetic materials have been used in the past to bypass the use of autolgous tissue 
sources. Desgrandchamps et al published two reports in which ureters constructed from a 
silicone polytetrafluoroethylene bonded tube was introduced into the pyelocaliceal renal 
graft cavities and placed subcutaneously into the suprapubic area where it was eventually 
guided into the bladder within human patients. (Desgrandchamps, 1995, 1998)   A mean 2.5 
year follow-up demonstrated that all tubes were patent and displayed no evidence of 
encrustation or obstruction. More recently, xenogenic accellular collagen membranes have 
also been used with limited success. (Koziak, 2004)  The aforementioned studies provide 
evidence that various tissues derived and artificial matrices can be used for ureteral 
reconstruction. In order to further improve on the design and physiological function of the 
ureter, smart scaffolding material possessing antimicrobial attributes or capable of growth 
factor release, for example, may be incorporated into this setting such as those found in self 
assembling nanomolecules. 
2.3 The urinary bladder 
The urinary bladder is a hollow, musculocutaneous organ whose primary function is to 
expel waste products in the form of urine from the body. Damage or insult to this organ 
leads to bladder dysfunction which can have dire clinical consequences on upper and lower 
urological tracts including renal insufficiency with eventual renal failure. Patients suffering 
from severe bladder dysfunction caused by developmental defect, often resort to surgical 
means to stabilize poor bladder function. The various forms of spina bifida present the 
clinician and basic scientist alike with a battery of issues stemming from gross anatomical 
restructuring to the fine aspects of physiological function. The typical procedure to alleviate 
problems associated with the neurogenic bladder includes bladder augmentation 
cystoplasty. What is considered the “gold standard” procedure for patients suffering from 
end stage neurogenic bladder, a portion of the pathological, native bladder undergoes 
cystectomy. (Zini, 2004; Husmann, 2004) A detubularized portion of the bowel is then 
affixed to the cystectomized area of neurogenic bladder and hence serves as a neo-bladder 
in order to increase capacity. As the bladder is considered functional, it still lacks key 
attributes of a normally functioning bladder including sensory and contractile/expansion 
responses requiring lifetime self-catheterization. The reconstructed bladder also possess 
inherent complications including electrolyte imbalances as an absorptive tissue has been 
used to replace an excretory tissue; the high potential of infection; excess mucus formation; 
pronounced stone formation; spontaneous perforation, and the increased likelihood of 
malignant transformation. (Bankhead, 2000)  Although the augmentation cystoplasty 
procedure is considered standard care for this situation, it is still a stopgap measure.  
The biomedical applications of regenerated tissue took its roots from the pioneering work of 
Langer and colleagues. (Vacanti, 1988; Langer, 1993)  Within these studies, it was 
determined that donor derived cells could be seeded upon synthetic, biodegradable scaffold 
materials and subsequently manipulated in vitro for eventual in vivo applications. Applying 
these basic principles of cell biology and engineering, Atala and colleagues embarked upon 
a mission to recapitulate functional urological tissue with the goal of clinical applicability. 
Initial studies utilizing rabbit derived urological tissue subsequently seeded upon 
polyglycolic acid (PGA) meshes and implanted into the tissue within and adjacent to the 
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peritoneal cavity of athymic mice yielded poignant results. (Atala, 1992) Rabbit derived 
urothelium was able to proliferate and populate the PGA scaffold to an approximate 3 cell 
thickness while retaining key urothelial markers after 30 days in vivo. This initial study set 
the stage for several other studies that continued to evaluate the roles of specific cell types 
combined with synthetic scaffolds for bladder regeneration. (Atala, 1993, 1998)  
Concurrently, studies by Knapp et al and others were evaluating the use of small intestinal 
submucosa (SIS) as an alternative biological scaffold for bladder tissue engineering. (Knapp, 
1994; Kropp, 1995)  The results from these studies seemed to suggest that SIS was a suitable 
biological material for the bladder augmentation process. However, in two separate studies 
by Ashley et al, unseeded SIS would be found to be highly pro-inflammatory. (Ashley, 2009, 
2010)  The seminal work that laid the foundation for future bladder regenerative studies 
came from Oberpenning et al (Oberpenning, 1999) Within this study, autologous sources of 
canine urothelial and smooth muscle cells were harvested then seeded onto polymers and 
subsequently expanded ex vivo. Completely cystectomized canines were then transplanted 
with this new bladder construct and observed for approximately a year. Very compelling 
data suggested that the engineered bladders demonstrated a normal micro-architecture, 
mechanical properties and the ability to store and express urine. This study set the 
foundation for a human clinical trial utilizing neurogenic urothelial and smooth muscle cells 
from spina bifida patients with myelomeningocele as a model system with the hopes that 
the bladder milieu could be recreated in human. (Atala, 2006)  Following bladder biopsies, 
these two cell populations were isolated and expanded ex vivo and subsequently seeded 
upon either a collagen/PGA hybrid scaffolds or collagen alone scaffolds. These composite 
scaffolds were anastomosed to the native tissue following an initial cruciate incision to the 
native bladder. An approximate mean 4 year follow-up revealed no statistically 
improvement in collagen only based scaffolds for a number of different urodynamic 
functions including capacity, leak point pressure, and compliance. PGA/collagen scaffolds 
encased in omentum appeared to display a very modest increase in bladder capacity. The 
approach taken by Atala et al was bold and extremely novel and provided highly relevant 
data for this specific patient population. However, the data presented within the work failed 
to acknowledge that utilizing a pathological source of cells at the onset of this work could 
possibly result in abnormal cellular behavior or possible reformation of a diseased bladder 
state. Characterization of bladder smooth muscle cells derived from patients with 
myelomeningocele indicates that cultured bladder smooth muscle cells possess different 
characteristics than their normal counterparts. (Lin, 2004; Beqaj, 2005)  Finally, the 
aforementioned augmented bladders continued to be non-contractile thus requiring the 
patients to presumably self catheterize for the remainder of their lifespan. Although 
groundbreaking in nature, much work needs to be performed in order to fully realize the 
goal of creating a functional bladder. 
2.4 The urinary sphincters 
The urinary sphincters are composed of a collection of muscles whose primary function is to 
prevent the premature leakage of urine from the bladder. (Feki, 2007; Delancey, 2004)  The 
internal urethral sphincter is located at the proximal portion of the urethra and is a 
continuation of the detrusor muscle consisting of smooth muscle cells. The external urethral 
sphincter is comprised of skeletal muscle and is situated inferior to the prostate in males and 
at the bladder's distal inferior end in females. (Koyanagi, 1980)  Disruption or dysregulation 
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of the sphincter system can lead to incontinence that encompass various forms including 
stress urinary incontinence, structural incontinence, urge and overflow incontinence as well 
as mixed incontinence. (Botlero, 2011; Siegler, 2004; Brubaker, 2011)   The economic costs of 
urinary incontinence are quite staggering and account for greater than $20 billion dollars per 
year within the United States. (Wilson, 2001)   Attempts to alleviate the dysfunction 
associated with incontinence have been manifested in various tissue engineering attempts to 
rejuvenate or replace poorly functioning sphincters. Yiou et al tracked the fate of muscle 
precursor cells that were implanted into a rat model of striated urethral sphincter injury. 
(Yiou, 2003)   Muscle precursor cells were able to adapt to their environment and form 
myotubules in which acetylcholine receptors were present. Urodynamic studies 
demonstrated a 41% restoration of sphincter function at approximately one month post 
muscle precursor cell implantation. A second study similarly utilized muscle derived 
progenitor cells in a denervated female rat urethra model. (Cannon, 2003)   Two weeks 
following cell injection, urethral muscle strips were analyzed under electrical field 
stimulation. Injected muscle derived progenitor cells greatly improved the amplitude 
associated with fast-twitch muscle contractions at a rate of approximately 87% as compared 
to control animals. The aforementioned studies and those that have incorporated the use of 
synthetic bulking agents such as poly(lactic-co-glycolic acid) (PLGA) microspheres have 
demonstrated alternative means in which to overcome obstacles associated with urinary 
incontinence. (Berjukow, 2004; Oh, 2006) The foundation that these works have created 
has resulted in over 50 clinical trials related to urinary incontinence. 
(http://clinicaltrials.gov)   The field continues to evolve at a rapid pace partially driven 
by a need to create a solution to this problem as well as the potential for high financial 
benefits.  
2.5 The urethra 
Urethral narrowing is the most common affliction affecting the urethra. Physical trauma or 
insult by bacteria or virus can result in an abundance of scar tissue caused the local invasion 
of  inflammatory cells as the body attempts to resolve the situation at hand resulting in 
stricture. Clinical presentation includes painful urination, decreased urinary output, dark 
colored urine, pelvic pain, and incontinence among some of the symptoms. (Ghoniem, 1994; 
Barbagli, 2007; Mangera, 2010)  Depending upon the anatomical location and the severity of 
the stricture, different techniques have been utilized to remedy stricture exacerbation. 
Urethroplasty has been successfully utilized as a treatment option to repair the stricture. 
One method is to excise the stricture from the urethra and then rejoin the opposing ends. A 
second approach requires tissue grafting from typically autologous sources of buccal 
mucosa, amniotic membrane, or saphenous vein tissue. (Mangera, 2010; Goel, 2011, Levine, 
2007, Shaeer, 2006)   Complications associated with this type of surgery include fistula 
formation, infection, and stricture reformation. (Olajide, 2010)   Tissue engineering 
approaches using synthetic and biologic matrices have also been investigated as alternative 
approaches to urethral repair. Derivatives of PLGA have been created to mimic buccal 
mucosa with the added benefit of possessing superior mechanical and elastic properties. 
(Selim, 2011)   Other biomaterials such as SIS, bladder acellular matrix (BAM), and acellular 
corpus spongiosum matrix (ACSM) have also been utilized in studies with favorable results. 
(Feng, 2010; Powers, 2010)   Since host inflammatory responses appear to be a major culprit 
behind stricture formation and its persistence, means to address this issue should be 
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explored.  One practical solution may be the localized delivery of anti-inflammatory agents 
into the affected area to prevent further stricture formation. This may be accomplished via 
a number of delivery vehicles including hydrogel releasing anti-inflammatory agents as 
well as self-assembling nanomolecules capable of down-regulating the cellular 
inflammatory response through surface expression of anti-inflammatory epitopes. 
Current research is focusing upon the creation of peptide amphiphiles that may be 
capable of such feats. Combined with the anti-inflammatory characteristics of 
mesenchymal stem cells, this one-two punch to either attenuate inflammation or act in a 
prophylactic manner may help with stricture development and other biologically relevant 
other pro-inflammatory situations. 
3. Stem cells and potential applications in urological regenerative medicine 
Stem cells can be described in several different embodiments such as those that are derived 
from embryonic sources or somatic (adult) in nature. The differential capabilities of these 
cells can further be sub-categorized as being either totipotent, pluripotent, or multipotent. 
Totipotent stem cells are a result of a fusion of sperm and egg that have undergone limited 
divisions during early embryological development in mammalian systems. (Mitalipov, 2009; 
Seydoux, 2006)   At this early stage of development, totipotent stem cells have the potential 
to become any type of cell in the body which also includes extraembryonic tissue. 
(Mitalipov, 2009; Seydoux, 2006)    As a zygote undergoes further differentiation, totipotent 
stem cells lose their ability to create whole organisms and become more lineage restricted, 
hence becoming pluripotent. Pluripotent stem cells can give rise to tissues of endoderm, 
ectoderm, and mesoderm origin, but not extraembryonic tissue and can be derived from 
both embryonic and somatic cells. (Pittenger, 1999, Thomson, 1998; Takahashi, 2007; Ko, 
2009)  Multipotent cells are greatly restricted in their ability to generate specific 
differentiated cell types and subsequently tissue. These cells retain the ability to self-renew 
and divide into daughter progeny, but these characteristics are greatly limited. A highly 
characterized population of cells that fits this definition is mesenchymal stem cells that have 
been described to differentiate into adipocytes, osteocytes, chondrocytes, and others. 
(Pittenger, 1999, Phadnis, 2011) 
3.1 Mesenchymal stem cells 
The hematopoietic system and its constituents have been extensively characterized at 
multiple levels via decades of research and clinical experiences.  The hematopoietic system 
found within the bone marrow of long bones in mammals consists of a hierarchy of cells 
originating from a primitive hematopoietic stem cell. The hematopoietic stem cell is capable 
of giving rise to all blood derived cells including those of lymphoid and myeloid origin. 
(Akashi, 2000)   Also residing in the bone marrow are non-hematopoietic multipotent 
mesenchymal stem cells capable of variable cellular differentiation as previously described. 
(Takahashi, 2007; Ko, 2009; Phadnis, 2011) The frequency of which bone marrow derived 
mesenchymal stem cells are found within long bones is approximately 0.001% to 0.1% of 
nucleated cells which include adipocytes, macrophages, osteoblasts, and reticular 
connective tissue. (Pittenger, 1999)  Therefore, fibroblast cells that reside in the bone marrow 
are not synonymous with mesenchymal stem cells. The plasticity demonstrated by 
mesenchymal cells can be utilized in a variety of regenerative medicine settings, especially 
those targeting urologic defects.  
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In a series of studies utilizing bone marrow derived mesenchymal stem cells from normal 
human, adult donors, Sharma et al demonstrate the phenotypic and physiological 
similarities between bladder smooth muscle cells and adult mesenchymal stem cells. 
(Sharma, 2009)   The mesenchymal stem cells utilized throughout this study as well as 
subsequent studies were an epitope defined population of highly purified mesenchymal 
stem cells. This study further demonstrated that both populations of cells can respond to 
agonist stimulation with statistically indistinguishable contractile responses in vitro while 
possessing similar contractile machinery. A second study by Sharma and colleagues utilizes 
adult mesenchymal stem cells in a nude rat bladder augmentation model. (Sharma, 2010a)  
Within the context of this study, bladder regeneration occurred more potently with 
mesenchymal stem cells than normal human bladder smooth muscle cells and controls. 
Scaffolds seeded with mesenchymal stem cells expressed high levels of bladder smooth 
muscle markers along with typical muscle architecture in the form of muscle fascicles. These 
scaffolds also demonstrated an approximate 1:1 muscle to collagen ratio at the termination 
of the experiment which was vastly different from bladder smooth muscle cell seeded and 
unseeded controls. A third and more recent study by Sharma et al again demonstrate the 
utility of mesenchymal stem cells in a bladder regenerative setting except in this instance, 
autologous sources of epitope defined mesenchymal stem cells were utilized to establish a 
novel bladder augmentation model in a non-human primate. (Sharma, 2010b)   Data from 
this study provides evidence that mesenchymal stem cell seeded scaffolds performed 
exceptionally as defined by physiological measurements and tissue phenotyping studies 
with a battery of proliferative and smooth muscle markers compared to controls. More 
importantly, this newly described augmentation model demonstrates potential clinical 
feasibility as this non-human primate is highly analogous to humans both anatomically and 
physiologically. Hence the use of autologous sources of non-pathological cells can be 
successfully utilized in a bladder regenerative setting. 
Although the aforementioned studies provided strong evidence for bladder regeneration in 
hemicystectomized animals,   future endeavors will require a great deal of scientific prowess 
to regenerate a fully functional bladder. Hence, the natural course of action would be the 
continuance of these studies. One aspect in conjunction with regenerating tissue is to create 
an environment that can provide a robust blood supply to developing tissue. Genetically 
modified mesenchymal stem cells carrying pro-angiogenic growth factors under the control 
of inducible promoters may aid in this function. A second strategy involves the use of 
nanomolecules capable of delivering much needed growth factors to tissues undergoing 
regeneration.  Rajangam et al demonstrate robust in vivo angiogenesis via the delivery of 
heparin binding nanostructures. (Rajangam, 2006)   The cross-pollination of stem cell 
biology with nanotechnology derived materials can potentially provide reliable and 
reproducible results when applied to urologic tissue regeneration which is the basis for 
future studies. 
There are several tissue sources in which mesenchymal stem cells can be identified and 
isolated. Two of those sources are found within adipose tissue as well as amniotic fluid 
which bathes the fetus in utero. These cell populations have been shown to function within 
urological settings. Dyslipidemia has been associated with a variety of poorly compliant 
physiological conditions including erectile dysfunction. (Huang, 2010)   Damage occurs to 
the cavernous endothelium and associated nerves through mechanisms that are not quite 
fully understood. In order to facilitate recovery, adipose derived mesenchymal stem cells 
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have been utilized to augment repair in the penis with the understanding that various 
factors secreted from mesenchymal stem cells promote re-growth of endothelium and 
improved nerve conduction. Within the context of this study, adipose derived mesenchymal 
stem cells were injected into the corpus cavernosum of dyslipidemic rats. Following a 
period of recovery, erectile function was assessed and mean intracavernous 
pressure/arterial pressures ratios were superior to control samples. Increased levels of nitric 
oxide synthase and alpha smooth muscle actin were also observed. (Huang, 2010) This 
study provides preliminary evidence that adipose derived mesenchymal stem cells can be 
used to ameliorate the urologic complications that arise in urologic settings. In order to 
obtain continual exposure of these factors in the afflicted areas, seeding these cells upon 
implantable nanofabricated materials may allow for immediate regeneration accompanied 
by long term maintenance. Nanofabricated materials can recreate specific cell niches in 
order to potentially enhance the regenerative effect and this topic will be discussed in 
greater detail within subsequent sections. (Murtuza, 2009) 
Adipose derived mesenchymal stem cells have also been utilized in bladder regenerative 
settings and provide a means to obtain a multipotent cell source through adipose tissue 
aspirates. (Jack, 2009) Adipose derived mesenchymal stem cells maintain an approximate 
3% of all nucleated cells within a sample of aspirate. Jack et al seeded adipose derived 
mesenchymal stem cells upon PLGA scaffolds and implanted them in 50% cystectomized 
athymic nude rats. 12 weeks post-transplantation, physiological measurements were 
assessed as well histological and immunofluorescent analyses, and organ bath studies. All 
data derived from this study indicate that the adipose derived mesenchymal stem cells 
perform similarly or better than control samples in almost every biological aspect. The 
novelty of this study obviously involves the use of this unique population cells. Future 
studies involving potentially sub-total cystectomized large animal models will hopefully 
provide a great deal of physiological information that may be applied to the human condition. 
The recently described characterization of amniotic fluid mesenchymal stem cells offers 
another potential alternative cell source that may be applied to urologic tissue engineering. 
Initially described by In 't Anker et al, 2ml of  second trimester amniotic fluid was obtained 
through transcervical isolation. (In’t Anker, 2003) Subsequent cell populations were cultured  
in vitro and coerced to undergo terminal differentiation where they demonstrated 
differentiation into adipocytes and osteocytes. Transplantation studies also provided 
evidence that these cells could be used in an allogeneic setting, which suggests that these 
cells may possess a greater immune-privileged status than their adult counterparts. The 
application of amniotic fluid derived mesenchymal stem cells in a bladder injury model 
convincingly demonstrates the wound healing potential of these cells. (De Coppi, 2007)  The 
direct injection of amniotic fluid derived mesenchymal stem cells into the cryo-injured 
bladder resulted in markedly reduced levels of smooth muscle hypertrophy but also 
demonstrated a limited level of smooth muscle cell regeneration which may have been 
attributed to inadequate numbers of injected cells since a dose response curve was not 
performed.  Although both experimental procedures describe this source of cells as potent in 
function, the means in which they are acquired are highly invasive and pose great risk to 
fetus and mother. It is estimated that 1 in 300 women experience fetal loss, infection, 
cramping/vaginal bleeding or other complications during or following amniocentesis. 
(Simpson, 2007) The isolation and subsequent banking of these cells may allow a convenient 
means for future therapies in both autologous and allogeneic settings. 
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3.2 Endothelial progenitor cells 
The lack of a properly vascularized graft is the bane of many tissue engineering studies 
regardless of the tissue attempting to be regenerated. Inadequate or improper 
vascularization leads to poor tissue development or graft failure of implanted cell/scaffold 
composites. This is evident towards the center of grafted composites as these areas are 
typically inaccessible to nutrient and gas exchange potentially resulting in a necrotic core. A 
manner in which to avoid the aforementioned scenarios would be to utilize autologous 
sources of endothelial progenitor cells. These cells could promote vascular growth even at 
the most cell dense levels of the graft since the endothelial progenitor cells can 
simultaneously be seeded along with other bladder cell types thereby encouraging vascular 
growth. Endothelial progenitors can typically be isolated from either the bone marrow or 
rather innocuously from the peripheral blood as circulating endothelial progenitor cells. 
3.2.1 Bone marrow derived endothelial progenitor cells  
It was initially speculated that cells that were destined to become constituents of blood 
vessels as a result of vascular growth were present throughout embryonic and early stages 
of fetal development. This was later revealed to be somewhat inaccurate with the advent of 
specific antibodies utilized to phenotype specific cell populations.  The CD34+ hematopoietic 
stem cell has been greatly characterized over the last several decades and it has been 
demonstrated that subset populations derived from bone marrow sources have the capacity to 
either form functional vasculature in or contribute to its remodeling vivo. (Abu El-Asrar, 2009; 
Ruger, 2008; Baum, 1992; Takahashi, 1999)   CD34+/CD133+ cells derived from the bone 
marrow have provided evidence that this population can give rise to highly purified 
endothelial cells. (Quirici, 2001)  Sharma et al describe the in vivo potential of this cell 
population as it was seeded within a chicken chorioallantoic membrane model. (Sharma, 2009)  
Post experimentation analyses of this work clearly demonstrate the angiogenic potential of 
bone marrow derived CD34+/CD133+ cells as human specific vasculature was formed utilizing 
this model. Other derivatives of this cell population including CD34+/CD133+/VEGFR2+, 
CD34+/CD133+/VEGFR3+, CD34+/VEGFR2+, and CD133+/VEGFR2+ cells maintain similar 
properties. (Salven, 2003; Luppi, 2010) However some may argue that the CD34 epitope is not 
required to describe an endothelial progenitor/precursor cell, although those groups appear to 
be in the minority. (Friedrich, 2006) In all cases, the frequency of bone marrow derived 
endothelial progenitor cells is quite low, hence other alternatives cell sources should be 
examined for potential regenerative medicine purposes. 
3.2.2 Circulating endothelial progenitor cells 
The seminal discovery that endothelial progenitor cells were persistent throughout the 
vascular system gave a tremendous boost to a number of tissue engineering approaches. 
Approximately 11 years ago, Asahara et al describes a simplistic and non-invasive means to 
isolate circulating endothelial progenitor cells. (Asahara, 1997) By utilizing CD34+ cells 
isolated from peripheral blood, the study demonstrates that this population of cells was able 
to differentiate into endothelial cells in vitro while concurrently incorporating into sites of 
active angiogenesis in an animal model of ischemia. Data goes onto describe the concept 
that circulating endothelial progenitor cells can home to areas of pre-existing angiogenesis 
and contribute to the angiogenic process. Since this revelation, many studies have been 
performed that confirm the concept of circulating endothelial progenitor cells. (Dubois, 2011; 
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Baker, 2011)  One recent example demonstrates the construction of a tri-leaf heart valve seeded 
with circulating endothelial progenitor cells. (Sales, 2010) Data revealed that endothelial 
progenitor cells were able to colonize the heart valve and provide both interstitial and 
endothelial functions to the evolving valve. (Sales, 2010) This again demonstrates the potential 
utility of endothelial progenitor cells. The use of endothelial progenitor cells is pivotal for 
tissue regeneration and cannot be understated. The goal of utilizing endothelial progenitor 
cells for tissue regeneration is definitely not simplistic in the sense by just applying a 
population of endothelial progenitor cells to a graft and assuming angiogenic events. The 
shear number of molecules that are involved in the angiogenic pathway need to be carefully 
balanced in order to prevent aberrant results. This can be demonstrated as an over-abundance 
of localized vascularization leading to excessive bleeding and subsequent pathological issues.  
The strengths of using circulating endothelial cells are that they can be isolated in large 
numbers and more importantly, they can be isolated in an autologous fashion. The latter 
avoids a battery of immunological events and immunosuppressive therapies that may have to 
be endured for the lifetime of the patient. Unfortunately, works describing the use endothelial 
progenitor cells in urological tissue engineering is very limited and should be further 
investigated as this resource is being squandered.  
3.3 Neural stem/progenitor cells 
The greatest issue involved with urological based tissue engineering strategies (in this 
author’s opinion) is the recapitulation of functional nervous tissue. Although attempts have 
been made to provide neural functionality to urologic organs such as the bladder utilizing 
nerve re-routing techniques, these results have been met with skepticism and concern. (Xiao, 
2005; Kurzrock, 2010; Park, 2010) Thus, alternate avenues should be evaluated to create 
functional neural circuitry for urologic organs such as the use of stem cells. The initial 
isolation and identification of neural stem cells occurred in 1992 by Reynolds and Weiss. 
(Reynolds & Weiss, 1992)   Neural stem cells were isolated from the striatum of the mouse 
brain and under specific culture conditions coerced to differentiate into neurons and 
astrocytes. Further testing demonstrated morphological features that were indicative of 
functional neural cells. This seminal work provided compelling evidence that argued 
against the long established belief that brain derived tissue could not undergo neurogenesis 
after birth or damaging insult. Subsequent in vivo studies exploited the use of neural stem 
and more differentiated neural progenitor cells in a variety of in vivo settings as cells were 
also being isolated from peripheral nervous systems. (Gage, 2000)  One study in particular 
describes the transplantation of neural progenitor cells into the cortical region of the rat 
brain that underwent lesion induction. (Prajerova, 2010) Electrophysiological assessments of 
brain slices revealed the generation of action potentials created by the neural progenitor 
cells that were statistically greater than control samples. Evidence was also provided in 
which transplanted neural progenitor cells exhibited expression of differentiated neural 
markers by immuno-staining. (Prajerova, 2010)    
As of this writing, attempts to utilize bona fide neural stem or progenitor cells have not 
come to fruition in a urological regenerative medicine setting.  One study does report the 
use of neuronal-glial precursor cells which facilitated the mild improvement in bladder 
physiological function. These included various urodynamic parameters such as mean 
voiding pressure, capacity, bladder pressure, and mean contraction amplitude. These values 
were marginally better than control animals. (Temeltas, 2009)  It is quite apparent that a 
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considerable amount of research is required to address the major concerns regarding 
urologic tissue neuro-regeneration. Cultivating cross-discipline approaches may provide a 
suitable means to an end. 
3.4 Embryonic stem cells 
The seemingly limitless therapeutic potential of human embryonic stem cells has 
commanded the attention of the scientific community since its initial discovery. (Thomson, 
1998)  Derived from the inner cell mass of the developing blastocyst, pluripotent embryonic 
stem cells can be isolated and possess several unique features. These are typified by high 
nuclei to cytoplasm ratios, very pronounced nucleoli, the capability of indefinite cellular 
propagation, and most significantly, the ability to differentiate into cell types composed of 
all three germ layers. (Thomson, 1998)  The isolation and characterization of embryonic stem 
cells laid the foundation for literally thousands of studies that now spans multiple 
disciplines and aspects of regenerative medicine. (Birket, 2011; Nistor, 2005; Farzaneh, 2010)  
The use of embryonic stem cells is slowly making its way into the realm of urological tissue 
engineering. One study describes an in vitro culture environment in which conditioned 
media from primitive ureteric bud cells were used to support the differentiation of murine 
mesoderm cells initially derived embryonic stem cells. (Ren, 2010) The mesoderm cells were 
primed with activin and retinoic acid and subsequently forcibly differentiated into cells of 
renal lineage with the aid of the conditioned media. The strong inductive effect of the 
secreted molecules from the ureteric bud culture provides a means to elucidate potential 
mechanisms involved with mesoderm-renal cell lineage differentiation. A second, more 
recent study sheds light upon some of the molecules involved in the differentiation of 
murine embryonic cells into urothelium. (Mauney, 2010) As previously utilized in the 
aforementioned study by Ren et al, all trans-retinoic acid had the profound ability to induce 
pluripotent embryonic stem cells in to urothelial cells through a GATA4 and GATA6 
signaling pathway. Stimulation of the embryonic stem cells with all trans-retinoic acid 
caused a prominent increase in several uroplakin genes including UP1A, UP1B, UP2, and 
UP3B with a simultaneous down-regulation in the pluripotency factor OCT-4 compared to 
control cell populations. Concurrently, transcription factors GATA4 and GATA6 were also 
greatly up-regulated. GATA4/6 null embryonic stem cell lines demonstrated a marked 
reduction in uroplakin expression when undergoing similar treatments as compared to wild 
type controls. This data suggests a partial mechanism with regard to the inductive effect of 
all trans-retinoic acid and its ability to drive embryonic stem cells into urothelial cells. 
Several other studies have also utilized embryonic stem cells or embryoid body derived cells 
to generate bladder tissue to varying capacities. (Thomas, 2008; Kinebuchi, 2008; 
Lakshmanan, 2005) Unfortunately, a lack of follow-up studies has seemed to put a damper 
on this potentially ground breaking field of research.  
The utility of embryonic stem cells is obviously not without debate. Ethical and moral 
dilemmas have significant impact on political policy and are of grave concern for future 
studies utilizing embryonic stem cells that use federal funds to support research.  2001 saw 
restrictions placed upon the use and creation of embryonic stem cell lines, a ban that was 
later rescinded in 2009. The recent political atmosphere continues to be in a state of flux 
witnessed most recently by a recent court injunction that stopped the use of federal dollars 
to be used for embryonic stem cell research, thus effecting thousands of researchers. 
Although the injunction was temporarily stayed upon an appeal, it could set a damaging 
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precedent for the future. Privatized monies as found within the California Institute of 
Regenerative Medicine currently finance studies with embryonic stem cells with other states 
in pursuit. (http://cirm.ca.gov/for-researchers/researchfunding) Nevertheless, several 
clinical trials set forth by privately held companies such as Geron and Advanced Cell 
Technology are currently underway. (Strauss, 2010; http://www.advancedcell.com/news-
and-media/press-release) The controversies surrounded embryonic stem cell research in 
part fueled the scientific community to pursue other avenues of research that would lead to 
the identification of an alternative source of pluripotent stem cells. 
3.5 Induced pluripotent stem cells 
Preliminary observations involving studies with somatic cell nuclear transfer into recipient 
oocytes resulted in cell populations that displayed features that were highly analogous to 
embryonic stem cells in morphology and function. (McGrath, 1983; Campbell, 1996)  Via 
successive rounds of a highly selective molecular screening process, four genes were 
determined to be essential in the de-differentiation of terminally differentiated cells back to 
a pluripotent, embryonic-like state. Takahashi et al produced the first generation of induced 
pluripotent stem cells from human adult fibroblasts with the over-expression of four 
transcription factors including Sox2, Oct3/4, c-Myc, and Klf4. (Takahashi, 2007) These cells 
possessed embryonic stem cell-like qualities as they could differentiate into cells of 
endoderm, mesoderm, and ectoderm origin; were able to form teratomas in vivo; and  
proliferate indefinitely without losing their pluripotency. A subsequent study from Yu et al 
utilized a similar procedure derived from the Takahashi study but determined that a 
slightly different cocktail of genes (or proteins) could induce the same effect. (Yu, 2007) 
OCT4, SOX2, NANOG, and LIN28 were identified as pluripotency factors that had the same 
effect as the aforementioned gene set. Since a slightly different set of genes was utilized in 
the second study, it would be easy to speculate that different combinations of genes or yet to 
be identified factors that are tissue specific may be utilized to create pluripotent cell lines.  
This groundbreaking work led to a number of other studies focusing on specific cell type 
and disease states. (Moretti, 2010; Ebert, 2009) However, with each great discovery come 
certain drawbacks. It has been recently demonstrated that induced pluripotent stem cells 
outwardly function similarly to embryonic stem cells, but the gene expression signatures 
possessed by each cell type are quite different. (Chin, 2009) This is most likely a result of 
differential promoter binding by the reprogramming factors. Other studies also demonstrate 
the detrimental effects that coerced cellular reprogramming may induce upon target cell 
populations. (Hussein, 2011; Lister, 2011) The use of induced pluripotent stem cells in 
urological settings (excluding spinal and nerve injury scenarios) is still in its infancy with a 
paltry number of studies. (Morizane, 2009) As more data emerges with regards to the 
molecular machinery involved with the reprogramming process (along with potential 
consequences), perhaps these data will be applied to future urological regenerative 
medicine based studies. 
4. Polymeric materials and their potential applications in urologic 
regenerative medicine 
The choice of scaffold material is of paramount significance in determining the outcome of 
implanted cell/scaffold composites. There are a wide variety of scaffold materials that vary 
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greatly in composition, texture, mechanical and surface characteristics that could potentially 
be applied in a urological regenerative medicine setting. A number of these materials have 
been previously discussed in great detail such as bladder acellular matrix, small intestinal 
submucosa, varying embodiments of poly(lactic-co-glycolic acid) and polyglycolic acid, and 
collagen. Similarly, other chemically synthesized nano- and macro- based structures are also 
pivotal in creating hospitable environments for tissue growth and development. The focus 
of the forthcoming section will concentrate on relatively newly described elastic based 
materials that may be utilized for urological tissue engineering along with bioactive 
peptides and nanomolecules. 
4.1 Synthetic elastomeric substrates for urological tissue engineering 
4.1.1 Poly(diol citrates) 
The mechanical properties that contribute to the overall composition of various urologic 
organs in part define its ultimate structure and function, specifically with regard to  
the urinary bladder. The urinary bladder is a very dynamic organ as demonstrated by  
its wide elastic properties further exemplified by its ability to undergo repeated 
contractile/expansion cycles without permanent deformation. Characterization studies of 
human urinary bladder tissue describe the elastic modulus to be within the low-hundreds of 
kPa (kilopascal) (Dahms, 1998). Commonly used scaffolds for urinary bladder tissue 
engineering such as non-woven polyglycolic acid and poly(lactic-co-glycolic acid), and 
collagen typically exhibit elastic moduli in the giga- and megaPa range. These features 
predispose this materials to possess poor elongation characteristics of <10% hence making 
them unsuitable for functional urinary bladder replacement strategies. (Middleton, 2000) It 
has also been demonstrated that degradation byproducts of these polymers contribute to a 
localized decrease in pH which can have a negative impact on cell function, including 
decreased collagen synthesis and impaired cellular differentiation capacity. (Kohn, 2002) 
Cyclical mechanical forces have also been demonstrated necessary for bladder smooth 
muscle growth and development while static and non-contractile environments are less 
likely to produce robust contractile responses. (Heise, 2009) POC [poly(1,8-octanediol-co-
citrate)] is a relatively newly described member of a family of diols which is a synthetic 
polymer that has a wide range of applications including those for very elastic tissues such 
blood vessels, orthopedic applications, and perivascular wraps. (Yang, 2005; Qiu, 2006; 
Serrano, 2011) The elastic potential of this polymer is dependent upon several 
polymerization properties including the length and temperature of scaffold crosslinking. 
This allows for scaffold customization with regard to elastic potential. Sharma et al 
demonstrate the use of POC in a bladder augmentation model using bone marrow derived 
mesenchymal stem cells. (Sharma, 2010) Data from this study suggests the synthesis of a 
POC film that has elastic properties approaching that of a native human bladder and the 
ability of the POC scaffolds to undergo elongation up to 137% of their initial length. In vivo 
data suggests a high regenerative potential when utilizing POC/cell seeded composites as 
demonstrated by superior muscle to collagen ratios 10 weeks post-implantation (as 
compared to controls).  The non-toxic, degradative by-products of POC also appear to limit 
the level of stone formation with the context of this study, which may aid future bladder 
regenerative studies. Lastly, data also suggests that POC can be chemically modified to 
release pro-angiogenic growth factors over-time that contributes to robust levels of 
angiogenesis in vivo. (Sharma, unpublished data) 
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4.1.2 Elastomeric poly(ester urethane)urea 
A second well described elastomeric compound, poly(ester urethane)urea (PEUU), can also 
be configured into several different forms including those consistent with blood vessels 
while retaining elastic properties. (Stankus, 2007) By concurrent electrospraying and 
electrospinning of vascular smooth muscle cells and PEUU, respectively, a tubular conduit 
containing  the cells was formed with uniform cellular distribution in a radial and 
circumferential manner. Further testing revealed the ability of the material to remain 
sutured, while maintaining compliancy that was similar to native arteries. Modification of 
PEUU also demonstrates the ability to control gene expression utilizing a cleverly created 
gene induction system. (Baraniak, 2011)  Further modifications also allow for the release of 
bioactive molecules of insulin-like growth factor-1 and hepatocyte growth factor. (Nelson, 
2011)  Although this material has not been utilized in a urological regenerative setting to 
date, the implications of this material are obvious as this material could be structured for 
urinary bladder regenerative studies or the creation of synthetic ureters. An overly 
simplistic study design would include the seeding of porous scaffolds with relevant bladder 
cell types as previously described by Baraniak et al accompanied by the appropriate 
functional testing and immunohistochemical analyses. The added benefit of  utilizing PEUU 
is its ability to become modified so that relevant genes such as those found within urologic 
epithelial stem cells may contribute to regeneration, for example. (Pascal, 2007) It is hopeful 
that studies involving PEUU and urological tissue engineering will be seen in the not too 
distant future. 
4.2 Bioactive peptides and peptide amphiphiles for regeneration and wound healing 
Polymeric materials which are enhanced with bioactive peptides show perhaps the greatest 
degree of promise for application in tissue regeneration scaffolds. Short peptide sequences 
originating from the cell binding regions of extracellular matrix (ECM) proteins can be 
incorporated into a graft material to obtain biospecific adhesion of cells. RGD (arginine-
glycine-aspartic acid), the most commonly used peptide in cell adhesion studies, originating 
from fibronectin, collagen, fibrinogen and other ECM proteins, enhances adhesion and 
spreading of most cell types (fibroblasts, endothelial, and smooth muscle cells) and interacts 
with several different integrin receptors. (Humphries, 1990; Massia, 1991) It has been shown 
in the past that migration of smooth muscle cells and fibroblasts is biphasically dependant 
on the concentration of RGD attached to the migratory surface with intermediate loadings of 
RGD displaying maximal mobility. (Olbrich, 1996; Mann 2002) Polymers containing RGD 
sequence have been used in several wound healing in vivo and in vitro applications. For 
instance, incorporation of RGD peptide into PEG hydrogels partially eliminated 
inflammatory reaction of a scaffold implanted subcutaneously in immunocompetent in 
c57bl/6 mice resulting in a reduced presence of macrophages. (Lynn, 2011) Hydrogels 
containing RGD peptide were able to promote healing of ulcers, partial thickness burn 
wounds, and encourage ingrowth of glial tissue in the rat. PHSRN (proline-histidine-serine-
arginine-glutamate), a cell binding peptide sequence has been found to act synergistically 
with RGD sequence for cell adhesion. (van der Veen, 2010; Davis, 2001) When applied 
individually it can stimulate invasion of ECM by keratinocytes and fibroblasts in vitro and it 
can enhance the re-epithelialization and concentration of dermal wounds in healing-
impaired diabetic mice. (Livant, 2000) Other peptides sequences such as laminin-derived 
YIGSR (tyrosine-isoleucine-glycine-serine-arginine), LRE (leucine-arginine-glutamic acid) or 
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IKVAV (isoleucine-lysine-valine-alanine-valine) have potential application in nerve 
regeneration. (Fittkau, 2005; Pittier, 2005) YIGSR, unlike RGD and PHSRN, does not interact 
with the 67 kDa laminin binding protein. (Graf, 1987) In addition, YIGSR promotes the 
adhesion and spreading of many cell types including endothelial cells, fibroblasts, and 
smooth muscle cells. (Massia, 2011) It was found that PEG surfaces functionalized with cell 
binding peptide RGD and YIGSR, significantly increased microvascular endothelial cell 
migration rates relative to RGD alone. (Fittkau, 2005)  
Another group demonstrated that degradation of endothelial ECMs with bacterial 
collagenase releases proangiogenic peptide fragments which can stimulate epithelial 
responses to injury and wound healing in vivo. (Demidova-Rice, 2011)  It has been shown 
that sequences such as Col4-1, Col4-2, Fibr2, Fibr3, Ten1, Ten2, and Comb1 significantly 
increase the rate of sprout formation, which enhances cell-cell interactions and improves 
endothelial motility. Comb1 and Ten2 peptides contain the GXXPG sequence, which was 
previously reported to enhance endothelial migration and tube formation on collagen type I 
in vitro; both induce morphogenesis in a Matrigel-based assay. Comb1, as a larger 
combinatorial peptide with more complex tertiary structure, and two GXXPG sequences 
also stimulates cellular proliferation. The aforementioned sequences can also stimulate 
endothelial response to injury in complex environments where the cells remain viable for a 
prolonged time (up to one week). The 3D model of injury repair which was applied in that 
research consisted of two layers of Matrigel collagen mixture and a layer of endothelial cells 
sandwiched in between. Full thickness injury was created by aspiration, and the defect was 
filled with matrices containing serum, proangiogenic growth factors, or peptides. It was 
demonstrated that in addition to identification of promising proangiogenic or 
antiangiogenic therapeutics, the 3D model of injury repair can be employed to study the 
stability of wound healing compounds and to evaluate drug delivery systems. As described 
in this Chapter bioactive peptides play an important role in a wound healing process and 
tissue regeneration. Fabrication of scaffolds with a high specificity for the adhesion of a 
certain type of cells might require the use of a combination of bioactive peptides such as 
RGD, IKVAV, Ten 2, Comb 1, and biomimetic synthetic polymers, depending on the in vivo 
application.  
Peptide amphiphiles (PA) are small molecules that contain a peptide sequence and a 
hydrophobic segment such as an alkyl tail. (Silva, 2004; Rajangam, 2006)  Hydrophobic 
collapse of these filament-forming molecules under strong screening conditions leads to the 
display of biological signals on their surfaces in high density (on the order of 1015 signals per 
cm2). (Cui, 2010)  In vivo and in vitro studies have shown that certain PA molecules, bearing 
bioactive epitopes promote regeneration of spinal cord axons, angiogenesis, bone 
regeneration, cartilage repair, and selective differentiation of neural progenitor cells into 
neurons. (Sargeant, 2008; Webber, 2010; Silva, 2004) Previously, PAs were used to coat PGA 
microfiber scaffold for the improved attachment of smooth muscle cells. (Harrington,  
2006; Behanna, 2005) This PGA scaffold was submerged in a suspension of smooth muscle 
cells in media and modified with PA gel mixed with growth factors as a top layer for the 
entrapment of cells. The opposite face of the scaffold could them be modified using a second 
component, which in this case was a mixture of PGA and urothelial cells, since these cells 
could potentially send necessary signals to smooth muscle cells during regeneration. (Beqaj, 
2005; Imamura, 2007)  When the human bladder smooth muscle cells and urothelial cells 
where embedded in a PA-scaffold with a growth factor (bFGF) and incubated in vivo in a 
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subcutaneous nude rat model, it was found that the human bladder smooth muscle cells 
were retained and composed the majority of the scaffold cellular content. It was also found 
that the system which uses a combination of PGA, PA, growth factors and cells 
demonstrated higher levels of phenotypic alpha-smooth muscle actin than control scaffolds 
made of PGA and cells only. PAs offer a great potential in regenerative medicine due to 
their nanoscale filamentous assembly resembling the one in ECM, the ability to incorporate 
any bioactive epitopes into their structure, and propensity to form gels.  
4.3 Nano- and microstructured surfaces for bladder regeneration 
Nano- and microstructured surfaces offer great potential for a range of biomedical 
applications from biochips, bioarrays and biosensors to functional membranes and cell 
adhesion substrates. It is much easier to create nano- or micrometer patterns on surfaces 
such as metal, glass or silicon than on polymeric surfaces since the surface composition and 
flatness is much better defined. (Qin, 2010; Jackman; 1998)  The techniques that are usually 
employed for nano- and microstructuring of surfaces include nanoimprint lithography 
(NiL), microcontact printing, shadow-mask lithography, photolithography, chemical etching 
processes, robotic spotting techniques, and more. Unfortunately only very few of these 
techniques are suitable for the surface modification and structuring of (bio)polymers 
commonly used as the bladder regeneration materials such as PGA, PLGA, poly(L-lactic 
acid) (PLLA), poly(ε-caprolactone) (PCL), and poly(carbonate-urethane) (PCU). (Miller, 
2004; Pattison, 2006) Nanoscale roughness is believed to improve the adhesion of proteins 
due to its higher surface area and surface energy.  Surfaces functionalized with protein such 
as fibronectin, laminin, collagen I or IV, ECM-type of protein and surfaces with nanometer 
roughness visibly improve bladder cell adhesion and interactions with the substrate. This 
phenomena is important in bladder regeneration since many implanted polymeric 
membranes need to be relatively quickly and efficiently replaced by healthy host tissue. 
Tissue integration into the biomaterial must occur; therefore resident cells need to adhere 
appropriately to the substrate in order for subsequent cellular functions to occur at the 
implant site. Nanoscale roughness of biopolymers or synthetic biodegradable polymers 
used in bladder regeneration research can be achieved by numerous techniques including 
surface functionalization with nanometer-size fibers such as PAs, electrospinning, chemical 
etching, nano- and micromolding and more. (Harrington, 2006; Doshi, 1995; Thapa, 2003)  
The aforementioned techniques may be applied as potential methods for the fabrication of 
improved scaffolds for bladder regeneration. 
Alternative means to achieve nanostructured membranes for bladder regeneration research 
utilizes micro or nanomolding. PLGA or PU polymers can be easily cast into molds with 
pre-fabricated nanometer features made of poly(dimenthylsiloxane) (PDMS). (Thapa, 2003) 
The procedure relies on pouring a solution of a polymer (for example PLGA or PU) onto a 
PDMS master mold, curing the polymer until is solid and releasing the polymer from the 
mold simply by peeling the film off from the mold. The minimum size of the features that 
could be achieved is defined by the master mold. This process is commonly used in the 
fabrication of microcontact printing stamps for soft lithography purposes. In this process the 
mold is usually fabricated in silicon through photolithography or e-beam lithography and 
the polymer which is used for stamps is usually PDMS. (Xia, 1998) PLGA and PU 
nanostructured polymers showed advantage in ovine bladder smooth muscle cells adhesion 
over polymers with larger features. 
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An interesting method for the bladder surface nanostructuring is the application of 
nanoparticles to introduce nanoscale roughness or improve certain properties such as 
permeability of the scaffold. One example was recently introduced where hyaluronic acid 
(HA) modified PLGA nanoparticles (HA PLGA NPs) were applied for the modification of 
SIS as a scaffold for bladder regeneration to alter its permeability and simultaneously 
deliver pro-regenerative compounds. (Roth, 2010) When SIS scaffolds were modified with 
PLGA NPs of the size in the range of 200-500 nm the scaffold showed a decrease in 
permeability to urea when compared with unmodified scaffolds. In addition, PLGA 
modified scaffolds demonstrated significantly higher adhesion of endothelial cells in 
comparison to unmodified scaffolds. Introduction of pro-regenerative compounds into the 
SIS scaffold via modification of PLGA NPs with HA (which has been recognized for its 
ability to promote scarless wound healing), improved the SIS scaffold in vivo performance. 
HA was attached through electrostatic interaction to the positively charged PLGA NPs 
which were previously modified with polyethylene imine to produce cationic NPs. The 
attachment of particles to the SIS scaffold was conducted by incubation and absorption of 
particles from solution. The modified SIS membrane was investigated for angiogenesis and 
permeability studies. It was found that HA-NP SIS demonstrated a statistically higher 
number of blood vessels when compared with unmodified. In addition, HA-NP SIS 
significantly decreased or even eliminated the propensity to form calcifications, decreased 
urea permeability and improved full-thickness bladder regeneration.  
Electrospinning is one of the most commonly used techniques for the (nano)fiber formation. 
In this process, nanofibers can be formed through an electrically charged jet of polymer 
solution or polymer melt. The simplest setup for electrospinning is composed of a high 
voltage power supply, a polymer solution reservoir (e.g. a syringe with a small diameter 
needle), and two electrodes (one connected to the needle and the other to the surface of the 
collecting mat or other substrate). The polymer supply is connected with a power supply 
through an electrode clipped to the metal needle for electrospinning. Flow control pump can 
be used to precisely control the flow rate of the polymer solution which is spun onto a 
substrate. The fiber-collecting surface must be conductive in order to attract the electrospun 
polymer and can be either stationary or rotating plate for collecting nonwoven or aligned 
fibers, respectively. 
Electrospinning permits fabrication of biodegradable elastomers into matrices that can 
resemble the scale and mechanical behavior of the native extracellular matrix. There is a 
great selection of polymers available for the electrospinning of nanofibrous scaffolds used in 
tissue engineering applications. Moreover, this process can be easily scaled up making the 
transformation from small-scale laboratory research into large-batch processes feasible. 
(Greiner, 2008; Zhong, 2010)  In addition to being used to fabricate nonwoven mats for 
wound dressings, there is currently much interest in making scaffolds for bladder tissue 
engineering. (Roth, 2010; Gelain, 2008) Baker et al used a 3D electrospun nanoscaffold of 
polystyrene to determine whether the phenotype of cells isolated from the stroma of human 
ureter specimens could be modulated by growing cells within such scaffold. (Baker, 2008) 
Non-aligned scaffolds made out of fibers with mean diameter of 200 nm were used in that 
study. Unfortunately the analysis of SM-MHC protein expression in cultures grown in 3D 
revealed that those cultures failed to undergo differentiation. It was explained that 
nanostructured polystyrene scaffolds have a high propensity to adsorb serum which 
maintained stromal cell cultures in a synthetic non-differentiated phenotype. In this case, 
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the approach of growing cell cultures in a serum-free media on the 3D polystyrene scaffold 
did not bring positive results. It was found that despite of its promising advantages of 
electrospun scaffold, stromal cells did not differentiate primarily due to the high propensity 
of the scaffold to the absorption of proteins from the serum. However, serum-free media 
reduced the absorption of proteins but cells still showed a greatly reduced plating efficiency 
and cultures failed to survive.  
Findings describing the interactions between human bladder urothelial cells (TEU-2) and a 
scaffold composite consisting of an electrospun fibrous matrix made of PCU and PLLA  
fused to a thin film for potential use in urothelial tissue regeneration. (Kundu, 2011) Their 
results suggested that when electrospun scaffolds alone (without the thin film) were used, 
their fibrous surface structure while allowing good cellular adhesion, inhibited the 
proliferation of urothelial cells, whereas cells seeded onto thin films with non-fibrous 
surfaces proliferated quickly. In addition, it was found that cells on electrospun fibers 
demonstrated numerous cellular extensions along the matrix fibers, rather than the 
substantial cell-cell integrations. It was explained that this finding may suggest that the 
fibrous nature of the electrospun materials do not facilitate the formation of an intact 
urothelium. The addition of thin films onto electrospun scaffolds, enhanced urothelial cell 
proliferation, surface coverage, cell-cell interactions, and multilayering in vitro. Electrospun 
scaffolds alone offer highly porous structures and deep cellular penetration, however they 
are unlikely to provide a sufficient barrier to water and solute transport when not 
embedded in a biomimetic synthetic polymer. Furthermore, the three-dimensional structure 
of such scaffolds may affect cell proliferation, differentiation or adhesion.  
5. Conclusion 
The task to create functional organs as a replacement therapy is indeed quite daunting.  
Tissue engineering studies during the late 1980s and early 1990s laid the groundwork for the 
current windfall of clinical applications that have been deployed for organ replacement. The 
continual evolution of materials science influenced materials combined with discoveries in 
the field of stem cell biology provides hope that goals of regenerative medicine can be 
achieved. Although there have been many significant advances with regard to urologic 
tissue engineering, the field is still in its infancy. There is still a great need to pursue basic 
and clinical science studies in order to benefit those afflicted with urological trauma or 
disease.   
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